1-(4-((5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]-pyrimidin-4-yl)amino)phenyl)ethan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-((5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]-pyrimidin-4-yl)amino)phenyl)ethan-1-one
• 英文别名: 1-(4-((5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)phenyl)ethan-1-one；1-[4-(5,6,7,8-Tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-ylamino)phenyl]ethanone
• 化学式: C₁₈H₁₇N₃OS
• 分子量: 323.418
• InChiKey: WAMQEJJHTZFMCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-((5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]-pyrimidin-4-yl)amino)phenyl)ethan-1-one 、 2,5-二甲氧基苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 以76%的产率得到3-(2,5-dimethoxyphenyl)-1-(4-((5,6,7,8-tetrahydrobenzo-[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)phenyl)prop-2-en-1-one
  参考文献：
  名称：

  Thienopyrimidine–Chalcone Hybrid Molecules Inhibit Fas-Activated Serine/Threonine Kinase: An Approach To Ameliorate Antiproliferation in Human Breast Cancer Cells

  摘要：

  Apoptotic evasion by cancerous cells being one of the striking hallmarks of cancer has turned into a new arena of drug discovery. A large number of pathways reported that govern the apoptotic evasion have been reported. Fas-activated serine/threonine kinase (FASTK) is a member of Ser/Thr kinase family, and it has been implicated in the apoptotic evasion and, hence, the development of cancer. Keeping this in view, a series of novel thienopyrimidine-based chalcones have been synthesized and evaluated to modulate the FASTK mediated apoptotic evasion. Initial screening was done by enzyme inhibition assay and binding studies, which showed that out of 15 synthesized compounds, 3 thienopyrimidine-based chalcone derivatives possess considerably high binding affinity and enzyme inhibitory potential (nM range) for FASTK. Cell proliferation assessment of selected compounds was performed on HEK-293 and MCF-7 cells. For MCF-7 cells, compounds 2, 10, and 12 show IC50 values of 20.22 +/- 1.50, 6.52 +/- 0.82, and 8.20 +/- 0.61 mu M, respectively. Annexin-V and PI staining suggested that these molecules induce apoptosis in MCF-7 cells, arrest the cell cycle in the G0/G1 phase, and subsequently inhibit cell migration presumably by inhibiting FASTK and reactive oxygen species production. In conclusion, we have successfully designed, synthesized, and characterized thienopyrimidine-based chalcones that inhibit FASTK and induce apoptosis. These compounds may be exploited as potential anticancer agents.

  DOI：

  10.1021/acs.molpharmaceut.8b00566
• 作为产物：
  描述：

  5,6,7,8-四氢-[1]-苯并噻吩[2,3-d]嘧啶-4(1h)-酮 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 9.0h， 生成 1-(4-((5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]-pyrimidin-4-yl)amino)phenyl)ethan-1-one
  参考文献：
  名称：

  基于 Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate 的新型乳腺癌细胞凋亡诱导剂的发现：合成、体外和体内活性评估

  摘要：

  采用多组分合成方法合成了 2-氨基-4,5,6,7-四氢苯并[b]噻吩-3-羧酸乙酯 1。当氨基酯 1 与异硫氰酸乙酯反应生成苯并[4,5]噻吩并[2,3-d][1,3]thiazin-4-one 3.在DCM和Et3N中用氯乙酰氯酰化氨基酯1，得到酰化酯4。氨基-酯 1 被环化为苯并[4,5]噻吩并[2,3-d]嘧啶-4(3H)-one 8，它与一些烷基化剂反应导致在氮 9-13 处烷基化。酰肼 14 被用作合成子来合成衍生物 15-19。合成氯噻吩并[2,3-d]嘧啶20并与水合肼反应得到肼衍生物21，其用作获得衍生物22-28的支架。亲核取代反应用于从氯噻吩并 [2,3-d] 嘧啶 20 中获得化合物 29-35。 在抗癌疗法开发的过程中，评估了必需化合物在体外对 MCF-7 和 HepG 的细胞毒性-2 癌细胞系。12 种化合物显示出令人感兴趣的抗增殖潜力，IC50 为 23.2 至

  DOI：

  10.3390/molecules25112523

文献信息

• Design and Synthesis of 4-Anilinothieno[2,3-<i>d</i> ]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors
  作者：Soha R. Abd El Hadi、Deena S. Lasheen、Mahmoud A. Hassan、Khaled A. M. Abouzid

  DOI：10.1002/ardp.201600197

  日期：2016.11

  epidermal growth factor receptor 2 (HER‐2) is an attractive cancer therapeutic approach. In this study, new series of 4‐anilinothieno[2,3‐d]pyrimidines were designed, synthesized, and tested as dual EGFR/HER‐2 kinase inhibitors. Five compounds (8a, 8b, 8e–g) demonstrated low to submicromolar inhibition of both kinases with IC50 values of 1.2, 0.6, 0.3, 0.2, 0.4 μM and 8.2, 3.4, 1.3, 0.5, 2.7 μM for

  表皮生长因子受体 (EGFR) 和人表皮生长因子受体 2 (HER-2) 的双重抑制是一种有吸引力的癌症治疗方法。在这项研究中，新系列的 4-苯胺噻吩并 [2,3-d] 嘧啶被设计、合成并测试为双重 EGFR/HER-2 激酶抑制剂。五种化合物（8a、8b、8e-g）对两种激酶均表现出低至亚微摩尔的抑制，对 EGFR 和 HER-的 IC50 值为 1.2、0.6、0.3、0.2、0.4 μM 和 8.2、3.4、1.3、0.5、2.7 μM 2、分别。将 5,6-四亚甲基部分引入带有 4-(3-氟苄氧基)-3-氯苯胺尾的噻吩并嘧啶核，导致 EGFR 和 HER-2 抑制活性的有利增加。化合物 8f (IC50 EGFR/HER-2: 0.2/0.5 μM) 对某些特定 NCI 细胞系也表现出显着的细胞生长抑制作用，
• Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
  作者：Souad A. Elmetwally、Khaled F. Saied、Ibrahim H. Eissa、Eslam B. Elkaeed

  DOI：10.1016/j.bioorg.2019.102944

  日期：2019.7

  tyrosine kinase family is one of the most important targets in current cancer therapy regimens. In this study, we have designed and synthesized a series of thieno[2,3-d]pyrimidine derivatives as an EGFR and HER2 tyrosine kinase inhibitors. All the synthesized compounds were evaluated in vitro for their inhibitory activities against EGFRWT; and the most active compounds that showed promising IC50 values

  许多激酶的失调与癌症的发展直接相关，酪氨酸激酶家族是当前癌症治疗方案中最重要的靶标之一。在这项研究中，我们设计并合成了一系列噻吩并[2,3-d]嘧啶衍生物，作为EGFR和HER2酪氨酸激酶抑制剂。在体外评估所有合成的化合物对EGFRWT的抑制活性。并测试了对EGFRWT表现出有希望的IC50值的最具活性的化合物对突变EGFRT790M和HER2激酶的抑制活性。此外，测试了这些化合物对四种癌细胞系（HepG2，HCT-116，MCF-7和A431）的抗肿瘤活性。化合物13g，13h和13k对所检查的细胞系表现出最高活性，IC50值为7.592±0。相当于厄洛替尼的32至16.006±0.58 µM（IC50为4.99±0.09至13.914±0.36 µM）。此外，选择了最有效的抗肿瘤药（13k）进行进一步研究，以确定其对MCF-7细胞系中细胞周期进程和细胞凋亡的影响。结果表明，该化合物阻滞了细胞周期的G2
• Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation
  作者：Emad M. Gad、Mohamed S. Nafie、Elsayed H. Eltamany、Magdy S. A. G. Hammad、Assem Barakat、Ahmed T. A. Boraei

  DOI：10.3390/molecules25112523

  日期：——

  A multicomponent synthesis was empolyed for the synthesis of ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 1. An interesting cyclization was obtained when the amino-ester 1 reacted with ethyl isothiocyanate to give the benzo[4,5]thieno[2,3-d][1,3]thiazin-4-one 3. Acylation of the amino-ester 1 with chloroacetyl chloride in DCM and Et3N afforded the acylated ester 4. The amino-ester

  采用多组分合成方法合成了 2-氨基-4,5,6,7-四氢苯并[b]噻吩-3-羧酸乙酯 1。当氨基酯 1 与异硫氰酸乙酯反应生成苯并[4,5]噻吩并[2,3-d][1,3]thiazin-4-one 3.在DCM和Et3N中用氯乙酰氯酰化氨基酯1，得到酰化酯4。氨基-酯 1 被环化为苯并[4,5]噻吩并[2,3-d]嘧啶-4(3H)-one 8，它与一些烷基化剂反应导致在氮 9-13 处烷基化。酰肼 14 被用作合成子来合成衍生物 15-19。合成氯噻吩并[2,3-d]嘧啶20并与水合肼反应得到肼衍生物21，其用作获得衍生物22-28的支架。亲核取代反应用于从氯噻吩并 [2,3-d] 嘧啶 20 中获得化合物 29-35。 在抗癌疗法开发的过程中，评估了必需化合物在体外对 MCF-7 和 HepG 的细胞毒性-2 癌细胞系。12 种化合物显示出令人感兴趣的抗增殖潜力，IC50 为 23.2 至
• Thienopyrimidine–Chalcone Hybrid Molecules Inhibit Fas-Activated Serine/Threonine Kinase: An Approach To Ameliorate Antiproliferation in Human Breast Cancer Cells
  作者：Nashrah Sharif Khan、Parvez Khan、Mohammad Fawad Ansari、Saurabha Srivastava、Gulam Mustafa Hasan、Mohammad Husain、Md. Imtaiyaz Hassan

  DOI：10.1021/acs.molpharmaceut.8b00566

  日期：2018.9.4

  Apoptotic evasion by cancerous cells being one of the striking hallmarks of cancer has turned into a new arena of drug discovery. A large number of pathways reported that govern the apoptotic evasion have been reported. Fas-activated serine/threonine kinase (FASTK) is a member of Ser/Thr kinase family, and it has been implicated in the apoptotic evasion and, hence, the development of cancer. Keeping this in view, a series of novel thienopyrimidine-based chalcones have been synthesized and evaluated to modulate the FASTK mediated apoptotic evasion. Initial screening was done by enzyme inhibition assay and binding studies, which showed that out of 15 synthesized compounds, 3 thienopyrimidine-based chalcone derivatives possess considerably high binding affinity and enzyme inhibitory potential (nM range) for FASTK. Cell proliferation assessment of selected compounds was performed on HEK-293 and MCF-7 cells. For MCF-7 cells, compounds 2, 10, and 12 show IC50 values of 20.22 +/- 1.50, 6.52 +/- 0.82, and 8.20 +/- 0.61 mu M, respectively. Annexin-V and PI staining suggested that these molecules induce apoptosis in MCF-7 cells, arrest the cell cycle in the G0/G1 phase, and subsequently inhibit cell migration presumably by inhibiting FASTK and reactive oxygen species production. In conclusion, we have successfully designed, synthesized, and characterized thienopyrimidine-based chalcones that inhibit FASTK and induce apoptosis. These compounds may be exploited as potential anticancer agents.